1 The antihypertensive efficacy of a long acting formulation of the calcium channel blocking drug, nicardipine, was assessed using clinic and ambulatory (Remler M2,000) blood pressure measurements.
Introduction -
Nicardipine is a new dihydropyridine derivative. closely related to nifedipine in chemical structure and action (Seki & Takenaka, 1977) . It has been shown to be effective in hypertension when assessed using clinic blood pressure measurements in uncontrolled (Takabatake el al., Taylor et al., 1985) and short-term controlled trials (Asplund, 1985; Bellet er al., 1985) . Moreover, nicardipine in a dose of 40 mg twice daily has been sllown in an open study to llave a sustained antihypertensive effect as assessed by direct intra-arterial monitoring but with a high incidence of side effects (Jones el al.. 1983), possibly because of the lligl~ peak plasma levels associated with the standard-formulation used. A new formulation of nicardipine (containing 30 mg standard and 30 mg slow-release pellet fortnulations of nicardipine) has been designed with the object of providing a sustairied antillyperte~lsive effect between doses w11c11 given twice daily but with fewer side effects. The ainl of this study was to assess the efficacy of this formulation of nicardipine in a randomized double-blind placebo-controlled cross-over study using ambulatory blood pressure rccordings in addition to clinic measurements. Drug absorption was assessed by measuring plasma nicardipine levels before and 2 11 after dosing.
Methods
Twelve patients (eight female. four male. age range 32-65 years) with a lying diastolic blood pressure of 95 mmHg or greater were studied. Women who were pregnant or lactating and patients on drug therapy for any other illi~ess were excluded. The study protocol was approved by the hospital ethics conln~ittec and informed consent was obtained.
Study desigrr
Patients whose lying diastolic blood pressure remained within the limits of 95-110 mml-Ig after a 4 week-run-in phase on placebo entered a randomised double-blind, placebo-controlled. crospover study. Nicardipine in capsules was given in a dose of 60 mg (30 mg standard formulation and 30 mgslow release pellet formulation) twice a day, taken at 09.00 and 21.00 11. Treatment periods lasted 4 weeks and were separated by a 4 week wash-out period on placebo. Patients were seen every 4 weeks for measurement of blood pressure.. In addition at the end of each treatment period ambulatory blood pressure and heart rate recordings were made. Plasma samples were taken for nicardipine levels before and 2 11 after dosing.
Methods
Ambulatory blood pressure and heart rate were measured non-invasively at half-hourly ii~tcrvals using a semi-automated portable recorder, the Remler M2.000 (Remler Corp. Sail Francisco. C.A.), which is reliable and accurate (Fitzgerald et al., 1982) . The machine was operated by the patient from 09.00 to 22.00 h. All tapes were decoded by one operator. Clinic blood pressure was measured between 11.00 and 12.00 11 with the Hawksley random zero spl~ygmomanometer, Korotkov phase V being taken for diastolic pressure. Recordings were made with the patient lying after 5 min rest and standing after 2 mill with the arm supported at heart level (Petrie et 01.. 1986).
-,Plasma san~ples were taken before arid 2 11 after dosing at the end of each treatment period and stored at -20' C prior to assay for nicardipine levels by high-performance liquid chromatography (Wu er 01.. 1984). The lower limit of sensitivity of the assay was 1 ng ml-I.
Side effects were assessed during treatment periods by means of a check-list on which patients were asked to grade symptoms on a scale from 0-3 on a daily basis. In addition, at the end of each treatment period patients were given the opportunity to describe any further symptoms experienced during treatment.
Ambulatory blood pressure and heart rate wcre analysed using a computer programme designed to pair half-hourly readings on nicardipine with readings for the same time of day on placebo. Unpaired data were omitted. Average values for ambulatory blood pressure alid heart rate wcre computed for each patient on ~licardi-pine and on placebo. The means of two clii~ic readings for lying and standing blood pressure were used. Student's paired t-test was used for all comparisons and the influence of treatment. order and interaction effects were determined by the method appropriate for cross-over studies suggested by Hills & Armitage (1979) . A probability value of less than 5% was taken to be signi ficant .
Results
One patient was withdrawn from the study (see below). leaving seven females and four males. mean age 51.7 years and range 32-65 years. Mean f s.e. mean clinic lying blood pressure at the end of the placebo run-io phase was 173 + 6.61103 f 1.9 mmHg. Nicardipine significantly reduced clinic lying diastolic pressure only (Table  1 ). There were no period or interaction effects.
Mean ambulatory blood pressure was reduced from 164 f 5.3197 + 2.9 to 151 f 5.2188 f 2.4 mmHg (treatment difference 13 f 3.819 f 2.8 mmHg; P < 0.01) on treatment with nicardipine.
This effect was apparent within 2 h of the morning dose and was sustained for 8 11 (Figure l) , while mean ambulatory heart rate was unchanged with treatment (74.6 vs 76.7 beats min-I on nicardipine). Mean ( f s.e. mean) plasma nicardipine levels 2 11 after dosing were 28.6 2 5.9 ng ml-' (range 5.7 to 60.6 ng ml-I) and were 7.3 + 3.0 ng ml-' (range 3.7 to 14.3 ng ml-I) in samples taken before dosing. There was no correlatioll between changes in systolic and diastolic blood pressure and nicardipine levels 2 11 after dosing. dose dose Figure 1 Curves derived from the means of l~ourly values of ambulatory systolic and diastolic blood pressure on placebo (a) and nicardipine ( A ) after 4 weeks of treatment. n = 11; * P < 0.05. ** P < 0.01. *** P < 0.001.
One patient was withdrawn from the study after 10 days on nicardipine because of dizziness and flushing. Vasodilatory side effects such as headache, palpitations and flushing on nicardipine were noted by three patients.
Ambulatory blood pressure measurement demonstrated a significant blood pressure lowering effect which was sustained for 8 h with nicardipine 60 mg twice daily. This was achieved without any effect on heart rate. Furthermore this formulation of nicardipine was re,asonably well tolerated apart from the one patient who withdrew from the study. The duration of antihypertensive effect of the new formulation of nicardipine in a dose 60 mg twice daily is similar to that reported for tlie standard formulation in a dose of 40 mg twice daily (Jones et 01.. 1983) but with fewer side effects. A similar long-acting formulation of ~iicartlil>i~~c (~iicartlipitic LA) co~itaining 25% fast release and 75% slow release pellets in a dose of 50 mg twice daily in a randomised placeboco~itrolled cross-over study was also shown to have a sustained antihypertensive effect as asscsscd by both clinic and ambulatory blootl pressure rnonitoring witli few sitlc effects (Bellet et (11.. 1987) . From thcsc studies witli small ~i u~i~b c r s of patients it would appear that long acting forniulatiolis of ~iicardipine may retluce the i~icitlcnce of side cffccts associated with liigli peak plns~na concentrations of the drug while at tlie sanie time producing a sustained antihypertensive effect over the dosing interval.
To judge from the plasma levels absorption of tlie 60 mg dose of nicardipinc appears to be gradual. Single oral doses of 30 tng of tlie standard formulation of nicardipine have been shown to give peak plasma levels of up to 100 ng ml-' between 20 min and 2 h after dosing (Graham er 01.. 1984) whereas the highest 2 h level in the present study was only 60.6 ng ml-I.
Altliougli tlie magnitude of the fall of blood pressure in our study was similar with both clinic arid ambulatory measurement, tlie reduction of clinic blood pressure was statistically significant only for lying diastolic pressure. The failure of conventional measurement to detect a clinically significant blood pressure lowering effect when ambulatory measurement does. has been reported in several other small studies ( 1985) . Because of the paucity of data, the power of clillic readings to d i e c t statistically signkcant change was limited. whereas, an~bulatory measurement with the greater number of observations available, increased tlie power of these studies. mainly by reducing within-subject variability.
Applyi~ig tlie power calculations for cross-over studies described by Hill ~9 r Armitage (1979) t o the data in this study. eight patients would b e required if ambulatory measurement was used t o assess blood pressure lowering effect ( t o achieve a power of 85%). whereas 30 patients would b e needed with clinic measurement. Given tlie increasing demands for and the high costs of studies of blood pressure lowering agents, the potential of ambulatory blood pressure t o detect clinically significant reductions using smaller samples than those required using clinic measurement has important logistical implications (Conway el al.. 1988 ).
In conclusion the long acting formulation of nicardipine in a dose of 60 rng twice daily provided
